Cancer’s Vulnerability is Our Strength
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
Scientific Approach
Oncogenic transformations lead to DNA breaks that require repair for cancer cells to survive. This makes cancer cells vulnerable to targeted programs that disrupt DNA damage response and repair. Cyteir drug treatments have the potential to exploit this vulnerability by inducing synthetic lethality in tumor cells while sparing normal cells.
Cyteir’s Culture
With a pioneering spirit, putting patients first, we advance science passionately and collaboratively, in a fun learning environment. We value open, honest and transparent communication. We work diligently with respect for each other with a sense of urgency, integrity, accountability and purpose.
“The development and approval of PARP inhibitors have paved the way for additional, novel DNA repair and synthetic lethality-based therapies to address unmet needs in cancer treatment.”
Markus Renschler, MD
President and Chief Executive Officer